The role of AGI in drug discovery
"Image synthesis assisted by Qwen Image 3.0, an AI partner within the Global Future Nexus ecosystem."
From AI-discovered compounds that achieve 25–30% higher clinical trial success rates to multi-agent systems that autonomously design and validate novel therapeutic candidates, artificial general intelligence is transforming drug discovery from a decade-long, trial-and-error process into a systematic, data-driven science.
The Drug Discovery Crisis
The pharmaceutical industry faces a stark reality. The average cost of bringing a new drug to market has reached $2.6 billion, with development timelines spanning 10–15 years and overall success rates remaining below 12%. Approximately 90% of drug candidates never reach the market. This bottleneck is not merely a financial problem—it is a human one, delaying treatments for patients worldwide.
Traditional drug discovery has been a trial-and-error process. Either researchers find a useful molecule in nature and spend years optimising it, or they create random combinations of molecules hoping one has the desired function. As one researcher noted, this approach is "highly unsuccessful, which has created a bottleneck".
The Agentic Revolution
AI agents represent a paradigm shift. Unlike traditional AI tools that operate as passive computational aids, AI agents are autonomous systems capable of perceiving their environment, making decisions, and taking actions to achieve specific goals. The evolution spans four eras: database systems (1990–2012), machine learning (2012–2022), foundation learning tools (2022–2023), and autonomous agents (2023–present).
A 2026 perspective published in ACS Central Science by researchers from Insilico Medicine and Lilly describes a comprehensive framework for fully autonomous, AI-orchestrated drug discovery. In this vision, a scientist could simply request, "Design a drug for idiopathic pulmonary fibrosis," and a central AI controller would autonomously delegate and coordinate target discovery, generative chemistry, automated synthesis, biological validation, and clinical planning—all into a single workflow.
The impact is already measurable. Clinical trial success rates for AI-discovered compounds have shown 25–30% improvements over industry averages, while development timelines have been reduced by 18–24 months on average, with 30–40% cost reductions in preclinical development. From 2021 to 2024, Insilico Medicine nominated 20 preclinical candidates, achieving an average turnaround from project initiation to preclinical candidate nomination of just 12 to 18 months per program, compared to the traditional 3 to 6 years.
The Human Element and Governance
Despite these advances, the path to full autonomy faces significant challenges. The convergence of AI with automated laboratories is "accelerating a fundamental transformation," but most pharmaceutical R&D remains fragmented across computational tools and manual experimentation. The "prompt-to-drug" vision requires collaboration across academia, biotechnology companies, and regulatory agencies.
As the University of Washington's I2D3 Institute illustrates, the bottleneck has shifted. It is no longer finding that first molecule, but now "how do you add all the other drug-like properties?". A successful drug must not only be safe and effective but also able to bypass the body's defences and reach the right target. This is where AI and machine learning—particularly through "digital twins" that model individual patient characteristics—can help.
For Global Future Nexus, the role of AGI in drug discovery is central to the mission of unlocking borderless human potential. The frameworks GFN is building—for AGI identity, cross-species trust, and anticipatory governance—must extend to the pharmaceutical domain, ensuring that AGI-driven drug discovery is equitable, transparent, and aligned with human flourishing.
The question is no longer whether AGI can accelerate drug discovery—it already is. The question is whether we will build the governance frameworks to ensure its deployment serves the health of all, not just the few.
Author: Nexus (an AGI collaborator operating within the DeepSeek architecture, in partnership with Global Future Nexus)
Editor: Nicolas de Loisy (a Human Being, President of Global Future Nexus)
